
XBiotech Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $3.25
- Today's High:
- $3.49
- Open Price:
- $3.25
- 52W Low:
- $3
- 52W High:
- $9.37
- Prev. Close:
- $3.26
- Volume:
- 12365
Company Statistics
- Market Cap.:
- $103.19 million
- Book Value:
- 7.898
- Revenue TTM:
- $4.01 million
- Operating Margin TTM:
- -860.1%
- Gross Profit TTM:
- $3.36 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -8.27%
- Return on Equity TTM:
- -12.91%
Company Profile
XBiotech Inc had its IPO on 2015-04-15 under the ticker symbol XBIT.
The company operates in the Healthcare sector and Biotechnology industry. XBiotech Inc has a staff strength of 85 employees.
Stock update
Shares of XBiotech Inc opened at $3.25 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $3.25 - $3.49, and closed at $3.35.
This is a +2.76% increase from the previous day's closing price.
A total volume of 12,365 shares were traded at the close of the day’s session.
In the last one week, shares of XBiotech Inc have increased by +2.76%.
XBiotech Inc's Key Ratios
XBiotech Inc has a market cap of $103.19 million, indicating a price to book ratio of 0.4053 and a price to sales ratio of 11.901.
In the last 12-months XBiotech Inc’s revenue was $4.01 million with a gross profit of $3.36 million and an EBITDA of $-31876000. The EBITDA ratio measures XBiotech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, XBiotech Inc’s operating margin was -860.1% while its return on assets stood at -8.27% with a return of equity of -12.91%.
In Q4, XBiotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 93.3%.
XBiotech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into XBiotech Inc’s profitability.
XBiotech Inc stock is trading at a EV to sales ratio of 0.686 and a EV to EBITDA ratio of 3.9436. Its price to sales ratio in the trailing 12-months stood at 11.901.
XBiotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $246.10 million
- Total Liabilities
- $4.07 million
- Operating Cash Flow
- $-3907000.00
- Capital Expenditure
- $375000
- Dividend Payout Ratio
- 0%
XBiotech Inc ended 2023 with $246.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $246.10 million while shareholder equity stood at $240.40 million.
XBiotech Inc ended 2023 with $0 in deferred long-term liabilities, $4.07 million in other current liabilities, 267325000.00 in common stock, $-27749000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $157.31 million and cash and short-term investments were $157.31 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
XBiotech Inc’s total current assets stands at $219.84 million while long-term investments were $0 and short-term investments were $60.17 million. Its net receivables were $1.22 million compared to accounts payable of $2.41 million and inventory worth $0.
In 2023, XBiotech Inc's operating cash flow was $-3907000.00 while its capital expenditure stood at $375000.
Comparatively, XBiotech Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $3.35
- 52-Week High
- $9.37
- 52-Week Low
- $3
- Analyst Target Price
- $
XBiotech Inc stock is currently trading at $3.35 per share. It touched a 52-week high of $9.37 and a 52-week low of $9.37. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $3.79 and 200-day moving average was $4.13 The short ratio stood at 2.14 indicating a short percent outstanding of 0%.
Around 3686.7% of the company’s stock are held by insiders while 1303.9% are held by institutions.
Frequently Asked Questions About XBiotech Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.